ATBPF:OTC-Antibe Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.32

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Average Target Price

USD 1.40 (+341.64%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.38 (+0.57%)

USD154.36B 27.27 2.61
BHVN Biohaven Pharmaceutical Holdin..

-2.27 (-2.55%)

USD5.33B N/A N/A
ADCT ADC Therapeutics SA

+0.71 (+1.90%)

USD2.86B -99,999.99 N/A
ZYME Zymeworks Inc

+2.01 (+3.82%)

USD2.41B 300.20 N/A
MYOV Myovant Sciences Ltd

+0.48 (+2.02%)

USD2.15B N/A N/A
RCUS Arcus Biosciences, Inc

-0.25 (-0.92%)

USD1.77B N/A N/A
CVM CEL-SCI Corporation

-0.22 (-1.76%)

USD0.48B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

+0.17 (+0.79%)

USD0.34B N/A N/A
CRMD CorMedix Inc

-0.35 (-3.89%)

USD0.29B N/A N/A

ETFs Containing ATBPF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -90.68% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.68% 4% F N/A N/A
Trailing 12 Months  
Capital Gain -89.43% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.43% 4% F N/A N/A
Trailing 5 Years  
Capital Gain -72.14% 40% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.14% 40% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 53.89% N/A N/A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.89% N/A N/A 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 85.42% N/A N/A 29% F
Risk Adjusted Return 63.09% N/A N/A 91% A-
Market Capitalization 0.12B 48% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.86 41% F 12% F
Price / Cash Flow Ratio -10.28 61% D- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -151.43% 24% F 2% F
Return on Invested Capital -223.21% 23% F 0% N/A
Return on Assets -58.84% 33% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.24 89% B+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector